Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21419450 | 0.91 | MMP1 (0.39) | MMP1MMP3MMP7MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL21404876 | 0.87 | MMP1 (0.36) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL22815228 | 0.76 | MMP1 (0.42) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL13531452 | 0.75 | IDH1 (0.50) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL24327263 | 0.75 | MMP1 (0.39) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL21419451 | 0.75 | MMP1 (0.39) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL25162219 | 0.74 | MMP1 (0.40) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL26820254 | 0.73 | MMP1 (0.38) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL24636658 | 0.71 | IDH1 (0.43) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL4558007 | 0.71 | ALOX5 (0.53) | MMP1MMP3MMP7MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10821195-B2 | Compositions for therapeutics, targeted PET imaging and methods of their use | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190298864-A1 | COMPOSITIONS FOR THERAPEUTICS, TARGETED PET IMAGING AND METHODS OF THEIR USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298864-A1 | COMPOSITIONS FOR THERAPEUTICS, TARGETED PET IMAGING AND METHODS OF THEIR USE | NUCB2, NCL, SOST | MMP1 2383/4885MMP3 3362/4885MMP7 4487/4885 |
| US-10821195-B2 | Compositions for therapeutics, targeted PET imaging and methods of their use | NUCB2, NCL, SOST | MMP1 2383/4885MMP3 3362/4885MMP7 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.